FridayMar 04, 2022 12:43 pm

Utah Legislators Advance Approved Psychedelics Bill to Governor’s Desk

Last week, legislators in the state of Utah sent a measure to the governor that would establish a task force to conduct research on the therapeutic potential of various psychedelic substances and make recommendations on potential regulations for their legal use. The bill, which was introduced by Rep. Brady Brammer, was passed by both the House and Senate, with 68 to 1 and 23 to 1 votes respectively. It remains unclear where the state’s governor, Gov. Spencer Cox, stands on this issue. The recommendations made by the panel on these substances, which are defined as controlled substances under the Controlled…

Continue Reading

ThursdayMar 03, 2022 2:17 pm

How Investors Can Cash In on the Boom in the Psychedelic Field

The psychedelic sector has seen major growth in the past few years as consumer interest in psychedelic drugs as alternative medicines has increased. As research into psychedelics picks up steam and lawmakers discuss legalizing the substances, industry experts project that the psychedelics industry will experience significant growth over the next decade. Last year was a pretty good year for the nascent sector, and a new report indicates the industry could reach even greater highs in 2022. For investors who are looking to diversify their portfolio and invest in an emerging industry, psychedelics present an attractive opportunity. According to the Defiance…

Continue Reading

ThursdayMar 03, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted U.S. Patent for Deuterated DMT

Company announced the first officially issued patent Patent provides strong protection for Cybin’s growing IP portfolio of psychedelic-based compounds CYB004 has demonstrated potential efficacy at lower doses while increasing duration of drug effect that may alleviate common negative experiences In a milestone moment for psychedelic therapeutics company Cybin (NEO: CYBN) (NYSE American: CYBN), the company has announced its first official issued patent. The U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,242,318 to Cybin’s proprietary CYB004, the company’s lead investigational proprietary DMT compound. “From the outset, Cybin has focused on creating differentiated compounds that harness the potential efficacy of…

Continue Reading

WednesdayMar 02, 2022 2:16 pm

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Teams Up with Chopra Foundation to Foster Psychedelics Therapy Awareness

Dr. Deepak Chopra recently stated that there was an urgent need for more effective treatments in the mental health space, a statement with which Doug Drysdale, CEO of Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), agrees. Drysdale stated that he believed that the largest barrier in the advancement of the flourishing psychedelics industry was the stigmatization and misinformation concerning psychedelic compounds. He explained that many individuals who weren’t involved in the psychedelics sector knew so little about these compounds and had warped perceptions about what they could do, giving the example of a conversation he had with one scientist who…

Continue Reading

TuesdayMar 01, 2022 2:18 pm

Study Finds Psilocybin Use Lowers Odds of Being Arrested

A new study has linked the use of psilocybin with a reduction in the likelihood of an individual engaging in criminal behavior. Psilocybin is the active compound found in hallucinogenic mushrooms. Harvard University clinical psychology PhD candidate Grant Jones, the author of the study, stated that his interest in psychedelics grew as the substances gained more attention because of their treatment potential, having demonstrated that they could be used to relieve a number of mental health conditions. Jones explained that the purpose of the research was to investigate the relationship between criminality and psychedelics using population-based survey data, because not…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050